Objective: The aim of this study was to analyze the antithrombin-III (AT-III) activity in the serum in relation to other laboratory findings, including the serum albumin, total protein (TP), and uric acid (UA), and to assess the recovery of the AT-III activity in the serum after its administration in obstetrically ill patients. Patients and Methods: The medical records of 27 patients who were diagnosed to have disseminated intravascular coagulation (DIC) based on the obstetric DIC scores were reviewed and the relationships between the activity of AT-III in the serum and other laboratory findings were evaluated. The effect of administration of AT-III on the recovery of AT-III activity in the serum was also evaluated. Results: All the patients survived without any sequelae. The mean obstetric DIC score was 11.1 + 3.1 (range 8-19) and the mean blood loss during the first 24 hours was 3798 + 3,435 mL (range 480-16 208 mL). There was a significant correlation between the serum AT-III activity before the treatment and the serum albumin (r ¼ .67, P ¼ .001) and TP (r ¼ .59, P ¼ .021), but not serum UA. Seven patients required over 3000 IU of AT-III concentrate to obtain an increase in the serum AT-III activity to over 70%. The UA level in this group was significantly higher than that in the remaining patients. Conclusion: The serum AT-III activity was correlated with the serum albumin level before the start of treatment. Therefore, measurement of the serum albumin level before and during treatment is helpful.
Introduction
Disseminated intravascular coagulation (DIC) occurring in association with obstetric emergencies, such as placental abruption, is an acute and abrupt event, 1 and early diagnosis and prompt treatment are of utmost importance. Measurement of the serum activity of AT-III and administration of antithrombin-III (AT-III) concentrate has been reported to be very useful in the management of DIC. [2] [3] [4] [5] However, occasionally, no increase in the serum AT-III activity is noted after administration of the optimal dose of AT-III in obstetrically ill patients.
On the other hand, a good correlation has been observed between the serum AT-III activity and the serum albumin level, and the serum albumin level has been reported as a reliable predictor of the outcome of treatment in nonobstetric intensive care unit (ICU) patients. 6 In the current study, the clinical course of obstetric DIC patients was followed up and recovery of the serum AT-III activity after administration of AT-III concentrate was assessed in obstetrically ill patients; in addition, the serum AT-III activity was analyzed in relation to other laboratory findings, including the serum levels of albumin, total protein (TP), and uric acid (UA).
Materials and Methods
This study was conducted with the approval of the local ethics committee. The medical records of 27 patients who delivered at the Perinatal Medical Center, Tokyo Women's Medical University Hospital, between May 1, 2003 , and August 31, 2008, were reviewed. The patients were diagnosed to have DIC using the obstetric DIC scoring system established by Terao et al. 7, 8 This scoring system (Table 1 ) enables the diagnosis of DIC without the need to wait for the results of coagulation tests, and a score of !8 indicates a diagnosis of DIC. This scoring system has been demonstrated to be useful, especially for evaluating maternal complications. The patients were subdivided into 3 groups according to the basic obstetric complications listed in the classification of maternal death, International Statistical Classification of Diseases, 10th Revision (ICD-10) 9 : preeclampsia and its related disorders, placental abnormalities such as placental abruption and placenta previa, and postpartum hemorrhage.
The diagnosis of severe preeclampsia was based on the following criteria: blood pressure !160/110 mm Hg (measured at least twice > 6 hours apart) and/or proteinuria !2 g/d. 10 The diagnosis of the hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome was based on the clinical diagnosis of preeclampsia and the following laboratory abnormalities: (1) hemolysis, characteristic peripheral blood smear, serum lactic dehydrogenase (LDH) >600 U/L, total bilirubin >1.2 mg/dL, decreased hemoglobin and hematocrit;
(2) elevated liver enzymes, defined as aspartate aminotransferase (AST) >70 U/L, alanine aminotransferase (ALT) >50 U/L, and LDH >600 U/L; (3) a low platelet count, defined as <100 000/L. 11 The diagnosis of acute fatty liver of pregnancy (AFLP) was established on the basis of the clinical symptoms, complications, and laboratory evidence of acute hepatic dysfunction in the third trimester of pregnancy, with complete resolution of the liver dysfunction postpartum. Other causes of liver dysfunction, such as viral hepatitis, cholestasis of pregnancy, and biliary tract disease, were excluded. 11 Antithrombin-III concentrate (Mitsubishi Tanabe Pharma, Osaka, Japan) was administered at 3000 IU after establishing the diagnosis of DIC and confirming that the serum AT-III activity was less than 70%. This dose was used based on the recommendation of the government Health Care Insurance System in Japan, 12 which pays for the cost of medications and medical care of the patients. If the AT-III activity remained at less than 70%, administration of AT-III concentrate was repeated at the dose of 1500 IU. The patients were also treated with gabexate mecilate, fresh frozen plasma, platelet concentrate, packed red cells, dopamine, and a urinary trypsin inhibitor. Other treatments such as antibiotic administration, fluid resuscitation, and cardiovascular and respiratory support for each patient were determined by the physician in charge.
Measurement of the Serum Albumin and AT-III Activity
The serum albumin levels were determined by the bromocresol green method, using reflection spectrometry (Autoanalyzer 7700; Hitachi, Tokyo, Japan). Plasma AT-III activity was measured by a synthesized substrate assay (Coagrex-800 analyzer; Sysmexs, Tokyo, Japan). The serum UA concentrations were measured using an enzymatic method (Auto-analyzer 7700, Hitachi, Tokyo, Japan). The normal range for each of the tests is albumin 3.0 to 4.5 g/ dL; TP 5.0 to 6.5 g/dL; UA 5.0 to 6.5 mg/dL; and AT-III activity 70% to 110%. Only one of these items will be adopted as the score of underlying disease.
Correlations Between the Serum Albumin, TP and UA Levels, and the Serum AT-III Activity
The relationship between the serum AT-III activity before administration of the AT-III concentrate and other laboratory parameters was analyzed. To evaluate the effects of AT-III administration on the recovery of the serum AT-III activity, the serum AT-III activity was measured preadministration and 12, 24, and 48 hours after the first administration.
Statistical Analysis
The results were expressed as mean + SD. Analysis of variance, Mann-Whitney U-test, and Spearman's correlation coefficient were used for statistical analysis of the data; P values of less than .05 were considered to denote statistical significance.
Results
Twenty-seven consecutive critical patients diagnosed as having DIC were included in this study. Antithrombin-III concentrate was administered to 22 patients (81.5%). Seven patients (25.9%) required more than 3000 IU of AT-III concentrate to increase the serum AT-III activity to over 70%. This subgroup was designated as group A, whereas the remaining 20 patients were designated as group B. Table 2 shows the clinical profile of the patients included in this study, divided into 2 groups. The obstetric complications were preeclampsia and its related disorders (severe preeclampsia/eclampsia [n ¼ 6], HELLP [n ¼ 3], AFLP [n ¼ 2]), placental abruption or placenta previa (n ¼ 8), and postpartum hemorrhage (atonic bleeding [n ¼ 6] and uterine rupture [n ¼ 2]). Six patients were multipara and the outcomes of their previous pregnancies were uneventful. The mean obstetric DIC score was 11.1 + 3.1 (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and the mean blood loss during the first 24 hours was 3798 + 3435 mL (range 480-16 208 mL). A caesarean section was performed in 18 cases. In addition, abdominal total hysterectomy and hematectomy were performed in 6 and 2 cases, respectively. The DIC score on admission was closely correlated with the number of days required to achieve an improvement in the general clinical condition, including normalization of the blood pressure, heart rate, and urine output (Figure 1 , r ¼ .78, P < .001). All of the study patients survived, without any sequelae.
A significant correlation was observed between the serum AT-III activity and the serum albumin (r ¼ .67, P ¼ .001) and TP (r ¼ .59, P ¼ 0.021) levels, but not the serum UA levels, before the administration of AT-III concentrate (Figure 2) . Group A consisted of 5 patients with preeclampsia/eclampsia or HELLP, AFLP, and 2 patients with atonic bleeding. Table 3 shows a comparison of the characteristics between the 2 groups. There were no cases of placental abruption or placenta previa in group A. The serum UA level in group A was significantly greater than that in group B before the administration of AT-III concentrate (8.4 + 3.0 vs. 5.7 + 1.6, P ¼ .032).
The time course of changes in the serum AT-III activity following the administration of AT-III concentrate was compared between the 2 groups ( Figure 3 ). As illustrated in Figure 3 , the time course of changes in the serum AT-III activity was significantly different between the 2 groups (P < .0001). At 12 hours after the first AT-III administration, there was a significant difference in the serum AT-III activity between the 2 groups (P < .0001), although normalization of the serum AT-III activity was achieved in both groups at 24 hours after the start of the treatment. The serum AT-III activity was over 70% in all patients at the time of discharge from the hospital. In addition, there was no past history of thrombophilia.
Discussion
The mechanisms underlying decrease of the serum AT activity are multifactorial. 13 First, acute consumption of the molecules in the coagulation process is thought to be the main mechanism, reflected by an increase in the amount of the thrombinantithrombin (TAT) complexes in the serum. Second, decreased serum AT activity in DIC is also considered attributable to a decrease in the hepatic AT synthesis.
In addition, albumin leakage from the capillaries is known to be responsible for the reduction of the serum albumin levels noted during sepsis. 14 Because the molecular weight of AT-III (56 000) is even smaller than that of albumin (63 000), it is thought that in critical conditions, the capillaries would become increasingly permeable to not only albumin but also AT-III. 6 There are some hypotheses in connection with the reduction of the serum AT-III activity in obstetrically critical patients. 15 Patemoster et al stressed that the major cause of the reduced AT-III levels in women with preeclampsia is enhanced consumption. 16 In preeclampsia, there is a marked increase in the serum thrombin levels and, as a result, also in the amounts of the TAT complexes, but this is accompanied by an equally marked decrease in the circulating AT-III levels. 17, 18 Second, the reduction of the serum AT-III in these patients might be the outcome of reduced hepatic synthesis, as seen in HELLP/ AFLP. 19, 20 Third, it could reflect extrinsic loss, such as in patients with nephrosis. Bremme et al showed that preeclamptic women also lost more AT-III via the damaged kidney, as seen in some nonpregnant patients with nephrotic syndrome. 21 In the current study, a strong relationship was observed between the serum AT-III activity and serum albumin. This observation supports the reported mechanism of vascular leakage rather than enhanced consumption being the predominant mechanism underlying the reduction of the serum AT-III activity in obstetric patients with DIC. Therefore, it is very important to pay attention to the serum AT-III activity and serum albumin level before AT-III administration.
Critically ill obstetrically patients assessed by the obstetric DIC scores were treated with AT-III. Nearly a quarter of the patients in the present case series required more than 3000 IU of AT-III, regarded as the standard dose, to increase the serum AT-III activity to over 70%. Several explanations have been considered for this; first, in this subgroup (group A), preeclampsia and its related disorders were common. Although the number of DIC patients was insufficient to obtain results with sufficient statistical power, the tendency was, nonetheless, clear. In preeclampsia and its related disorders, the recovery of the AT-III activity after AT-III administration might be delayed because of the increased vascular permeability. Second, the serum UA level in patients treated with more than 3000 IU AT-III (group A) was significantly greater than that in group B. Elevated serum UA is an excellent marker of tissue ischemia, endothelial dysfunction, and oxidative stress, which could contribute indirectly to endotheliosis and increased vascular permeability, resulting in the necessity for higher doses of AT-III. 22, 23 In patients with hereditary AT deficiencies or nonseptic DIC, doses of AT ranging from 20 IU/kg per day to 50 IU/kg per day for 1 to 2 days are usually recommended to normalize the serum AT activity. However, in patients with septic DIC, these doses have been shown to be insufficient to achieve rapid correction of the serum AT activity. In a pilot study of 10 patients with septic DIC treated with a standard dose of 40 IU/kg per day for 4 days, the plasma AT activity could not be normalized in 5 patients; in the remaining 5 patients, normalization could only be obtained after the fourth day of treatment. 24, 25 Aibiki et al 6 reported that AT-III had a much shorter half-life (approximately 7.0 h) in acute, nonobstetric DIC patients than in congenital AT-III deficiency patients and normal participants (approximately 24 hours). 26, 27 The same pharmacodynamics of AT-III is probably also observed in critically ill obstetric DIC patients. Figure 3 . Comparison of the time course of changes in the serum antithrombin-III (AT-III) activity after administration of AT-III concentrate between the 2 groups. The serum AT-III activity increased significantly after treatment in comparison with the value measured before AT-III administration; *P < .05, **P < .01. The serum AT-III activity in group B (n ¼ 15) was significantly higher than that in group A (n ¼ 7), in which administration of more than 3000 IU of AT-III concentrate was needed to maintain the serum AT-III activity at over 70%. **P < .01, group A versus group B. White and black triangles represent the first and second administration of the AT-III concentrate, respectively.
This study was limited by the small number of patients and by the inclusion of a nonhomogeneous group of patients suffering from pregnancy induced hypertension, placental abruption, or postpartum hemorrhage, which poses a great difficulty in interpreting the effects of the treatment. Further study is therefore needed to confirm these observations.
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